当前位置： SCI文献检索 > JOURNAL OF THROMBOSIS AND THROMBOLYSIS期刊下所有文献 > Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices.

Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices.

Abstract：

:Continuous flow left ventricular assist devices (CF-LVAD) require therapeutic anticoagulation which is often interrupted for procedures or bleeding. Prior to the availability of four factor prothrombin complex concentrate (4F-PCC) in the United States, warfarin was held and its effects reversed by vitamin K or fresh frozen plasma. We evaluated the use of 4F-PCC for temporary warfarin reversal in patients with CF-LVADs and assessed outcomes. This analysis is a retrospective study of CF-LVAD patients who received 4F-PCC for warfarin reversal in the setting of bleeding or need for urgent or elective procedures. Primary outcome assessments included feasibility of administration in elective versus emergent situations, safety measured as incidence of thrombotic events, and change in INR after administration. In total, 37 CF-LVAD patients received 49 4F-PCC administrations. The average 4F-PCC dose was 1842 units (range 518-4292 units), or 22 units/kg (range 5.8-58 units/kg). 4F-PCC significantly decreased the mean INR from 2.9 to 1.7 (p < 0.0001) in 47 of 49 administrations; two patients did not have post infusion INR testing. No cases of new confirmed or suspected pump thrombosis, stroke, venous thromboembolism, arterial thrombosis, or myocardial infarction were observed within 30 days of administration of 4F-PCC. 4F-PCC administration for temporary warfarin reversal was demonstrated to be feasible, effective, and, safe in CF-LVAD patients and judged to be 96% effective in patients for whom data were available. We observed no thrombotic events attributed to use of 4F-PCC.

journal_name

J Thromb Thrombolysis

journal_title

Journal of thrombosis and thrombolysis

authors

Rimsans J,Levesque A,Lyons E,Sylvester K,Givertz MM,Mehra MR,Stewart GC,Connors JM

doi

10.1007/s11239-018-1680-8

subject

Has Abstract

pub_date

2018-08-01 00:00:00

pages

180-185

issue

2

eissn

0929-5305

issn

1573-742X

pii

10.1007/s11239-018-1680-8

journal_volume

46

pub_type

杂志文章

相关文献

JOURNAL OF THROMBOSIS AND THROMBOLYSIS文献大全
  • Circadian variations in pathogenesis of ST-segment elevation myocardial infarction: an optical coherence tomography study.

    abstract：:Previous studies have reported a circadian variation in the onset of ST-segment elevation myocardial infarction (STEMI). However, underlying mechanisms for the circadian variation have not been fully elucidated. We investigated the relationship between onset of STEMI and the underlying pathology using optical coherenc...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02220-6

    authors： Araki M,Yonetsu T,Kurihara O,Nakajima A,Lee H,Soeda T,Minami Y,Higuma T,Kimura S,Takano M,Yan BP,Adriaenssens T,Boeder NF,Nef HM,Kim CJ,Crea F,Kakuta T,Jang IK

    更新日期：2020-07-10 00:00:00

  • Genetic determinants of platelet response to clopidogrel.

    abstract：:Antiplatelet agents are the mainstay treatment in the prevention and management of atherothrombotic complications. However, a substantial interpatient variability in response to clopidogrel has been reported. Furthermore, patients with coronary artery disease and lesser platelet inhibition in response to clopidogrel a...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-011-0611-8

    authors： Kubica A,Kozinski M,Grzesk G,Fabiszak T,Navarese EP,Goch A

    更新日期：2011-11-01 00:00:00

  • M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice.

    abstract：:Heparin and low-molecular weight heparin (LMWH) are complex, heterogeneous polysaccharides used in the treatment of arterial and venous thrombosis. M118 is a novel LMWH with low polydispersity and pronounced anti-Xa and anti-thrombin (IIa) activity as compared to current LMWHs. To determine if M118 is effective in pre...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-009-0340-4

    authors： Chakrabarti S,Beaulieu LM,Reyelt LA,Iafrati MD,Freedman JE

    更新日期：2009-11-01 00:00:00

  • The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomes.

    abstract：:Pylephlebitis, or suppurative thrombophlebitis of the portal vein, typically occurs in the context of an intraabdominal infection or abdominal sepsis. Antibiotics are the mainstay of treatment. The role of anticoagulation in the management of pylephlebitis is controversial, and data regarding its impact on outcomes is...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-019-01949-z

    authors： Naymagon L,Tremblay D,Schiano T,Mascarenhas J

    更新日期：2020-02-01 00:00:00

  • The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.

    abstract：:Polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF), collectively known as Philadelphia-negative (Ph-negative) chronic myeloproliferative neoplasms (MPNs), MPNs represent the most common causes of splanchnic vein thrombosis (SVT), including Budd-Chiari syndrome (BCS) and portal ve...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章

    doi：10.1007/s11239-012-0738-2

    authors： Yonal I,Pinarbası B,Hindilerden F,Hancer VS,Nalcaci M,Kaymakoglu S,Diz-Kucukkaya R

    更新日期：2012-10-01 00:00:00

  • Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy.

    abstract：:Infarct artery stenting with adjunctive abciximab therapy is widely used treatment for patients with acute myocardial infarction (AMI). However, bleeding complications have been associated with a worse clinical outcome. Randomized trials in elective patients have shown that postprocedural protamine administration is s...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-010-0481-5

    authors： Parodi G,De Luca G,Moschi G,Bellandi B,Valenti R,Migliorini A,Carrabba N,Antoniucci D

    更新日期：2010-11-01 00:00:00

  • Magnesium Therapy for Acute Myocardial Infarction.

    abstract：:The use of magnesium therapy for acute myocardial infarction remains controversial despite recent clinical trials such as ISIS-4. Magnesium has numerous beneficial effects in the setting of myocardial infarction, including inhibitory effects on platelet aggregation. Clinical trials of magnesium therapy for myocardial ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/BF01064375

    authors： Rabbani LE

    更新日期：1995-01-01 00:00:00

  • Reasons for exclusion from intravenous thrombolysis in stroke patients admitted to the Stroke Unit.

    abstract：:Intravenous (IV) thrombolysis is the treatment in ischemic stroke, but only the minority of patients receive this medication. The primary objective of this study was to explore the reasons associated with the decision not to offer IV thrombolysis to stroke patients admitted to the Stroke Unit (SU). We conducted a retr...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-016-1406-8

    authors： Cappellari M,Bosco M,Forlivesi S,Tomelleri G,Micheletti N,Carletti M,Bovi P

    更新日期：2016-11-01 00:00:00

  • Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban.

    abstract：:Patients with heparin-induced thrombocytopenia (HIT) type II require anticoagulation with non-heparin immediate acting anticoagulants. Danaparoid may cross react with HIT-antibodies and lepirudin may generate anti-lepirudin antibodies influencing anticoagulation. We hypothesised, that the synthetic small molecular thr...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-005-0942-4

    authors： Harenberg J,Jörg I,Fenyvesi T,Piazolo L

    更新日期：2005-02-01 00:00:00

  • Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin.

    abstract：:Unfractionated heparin (UFH) plasma protein binding and elimination might be impaired in patients with chronic kidney disease (CKD-defined as creatinine clearance <60 ml/min). It is currently unknown at which UFH bolus dose persistent prolongation of activated partial thromboplastin time (aPTT) occurs in ST-segment el...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章

    doi：10.1007/s11239-015-1255-x

    authors： Kikkert WJ,van Brussel PM,Damman P,Claessen BE,van Straalen JP,Vis MM,Baan J Jr,Koch KT,Peters RJ,de Winter RJ,Piek JJ,Tijssen JG,Henriques JP

    更新日期：2016-04-01 00:00:00

  • Review of venous thromboembolism and race: the generalizability of treatment guidelines for high-risk populations.

    abstract：:The American College of Chest Physicians (ACCP) has established guidelines for the treatment of VTE, but the generalizability to all populations is unclear. In this review we analyzed the rate of reporting and enrollment of blacks and women in clinical trials cited in the ACCP guidelines for treatment of unprovoked VT...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-016-1352-5

    authors： Sullivan LT 2nd,Jackson LR 2nd,Thomas KL

    更新日期：2016-08-01 00:00:00

  • Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system.

    abstract：:Non vitamin K oral anticoagulants (NOACs) do not require regular monitoring but information about their pharmacodynamic effect may be importantin situations like trauma, stroke oremergent surgery. Currently, no standardized point-of-care test is available to evaluate the anticoagulant effects of NOACs. We evaluated th...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-017-1477-1

    authors： Bliden KP,Chaudhary R,Mohammed N,Muresan AA,Lopez-Espina CG,Cohen E,Raviv G,Doubleday M,Zaman F,Mathew B,Tantry US,Gurbel PA

    更新日期：2017-05-01 00:00:00

  • Direct Comparison of Aspirin Plus Hirudin, Aspirin Plus Heparin, and Aspirin Alone Among 12,000 Patients with Acute Myocardial Infarction Not Receiving Thrombolysis: Rationale and Design of the First American Study of Infarct Survival (ASIS-1).

    abstract：:While antithrombotic therapy of acute myocardial infarction is clearly beneficial, substantial controversy exists regarding the optimal regimen. In particular, while aspirin alone has proven highly effective in reducing rates of reinfarction, stroke, and death following acute coronary occlusion, heparin has not clearl...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/BF01062568

    authors： Ridker PM,O'Donnell CJ,Hennekens CH

    更新日期：1995-01-01 00:00:00

  • The effect of cessation of 2nd generation P2Y12 inhibitor therapy on platelet reactivity in patients 1 year after acute myocardial infarction.

    abstract：:To assess the effect of cessation of dual antiplatelet therapy (DAPT) regimens containing 2nd generation P2Y12 inhibitors on platelet reactivity, in patients who completed 12 months of DAPT following an acute myocardial infarction. Clinical data has shown an increased cardiovascular risk in the 90 days following cessa...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-018-1701-7

    authors： Witberg G,Bathish J,Bental T,Leshem-Lev D,Assali A,Kornowski R,Lev E

    更新日期：2018-10-01 00:00:00

  • Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism: comment.

    abstract：:Kuperman et al. found that patients with anemia had a higher risk of major bleeding (RR 2.84; 95% CI 2.52-3.39) in RIETE database. Anemia appeared to be an independent predictive factor for major bleeding [hazard ratio (HR) 1.95; 95% CI 1.72-2.20] in this registry. Unfortunately, selection bias due to enrolled patient...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 信件,多中心研究

    doi：10.1007/s11239-018-1668-4

    authors： Gaboreau Y,Zenatti N,Vermorel C,Imbert P,Bosson JL,Pernod G

    更新日期：2018-07-01 00:00:00

  • Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma.

    abstract：:The link between myeloma and thrombosis is well established. Monoclonal gammopathy of undetermined significance (MGUS) has also been associated with an increased risk of thrombosis. It was recently demonstrated that patients with myeloma display changes in thromboelastometry that may indicate a prothrombotic state. Th...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-014-1140-z

    authors： Crowley MP,Quinn S,Coleman E,Eustace JA,Gilligan OM,O'Shea SI

    更新日期：2015-02-01 00:00:00

  • Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis.

    abstract：:Anti-platelet agents or anticoagulants are administered for patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs) to prevent thrombotic events (TEs). However, there is a discrepancy between current guidelines and clinical practice in thromboprophylaxis and the varied incidence of TEs depending o...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-019-01809-w

    authors： Takaishi K,Tsukamoto S,Ohwada C,Takeuchi M,Kawasaki Y,Nagai Y,Mishina T,Yamazaki M,Isshiki Y,Kayamori K,Kimura K,Hino Y,Oshima-Hasegawa N,Mitsukawa S,Takeda Y,Mimura N,Iseki T,Nakaseko C,Sakaida E

    更新日期：2019-07-01 00:00:00

  • Thromboembolic events in patients with severe inherited fibrinogen deficiency.

    abstract：:Inherited afibrinogenemia and hypofibrinogenemia are rare bleeding disorders characterized by markedly reduced levels of fibrinogen in blood. Thrombotic complications in these disorders have been rarely described. We performed a multicenter retrospective study and reviewed the occurrence of thrombotic complications am...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s11239-015-1325-0

    authors： Rottenstreich A,Lask A,Schliamser L,Zivelin A,Seligsohn U,Kalish Y

    更新日期：2016-08-01 00:00:00

  • Effect of taurine on endotoxin-induced alterations in plasma asymmetric dimethylarginine, L-arginine and nitric oxide in guinea pigs.

    abstract：:The effect of taurine on the plasma levels of L-arginine, asymmetrical dimethylarginine (ADMA) and L-arginine/ADMA ratio and nitric oxide was investigated in experimental endotoxemia. L-arginine and ADMA levels were quantified by high performance liquid chromatography with fluorescence detector. Nitric oxide level was...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-007-0011-2

    authors： Balabanli B,Erdamar H,Türközkan N,Yaman H,Kurt Y

    更新日期：2007-08-01 00:00:00

  • Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.

    abstract：:Rivaroxaban is a direct factor Xa inhibitor, which is rapidly absorbed in the upper gastrointestinal (GI) tract. In large trials, it has been shown to be effective and safe in VTE treatment. However, in these trials patients with morbid obesity were not reported and it is unknown if the standard dosage of 20 mg rivaro...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-013-0891-2

    authors： Mahlmann A,Gehrisch S,Beyer-Westendorf J

    更新日期：2013-11-01 00:00:00

  • The impact of proton therapy on cardiotoxicity following radiation treatment.

    abstract：:Cardiac disease following radiation therapy represents a major consideration in the treatment of a variety of malignancies. Damage to the heart can manifest in a variety of pathologies including ischemic cardiac disease, cardiomyopathy, valvular dysfunction, arrhythmias, and pericarditis. This damage has been shown to...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章,评审

    doi：10.1007/s11239-020-02303-4

    authors： Frankart AJ,Nagarajan R,Pater L

    更新日期：2020-10-08 00:00:00

  • Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds.

    abstract：:The direct oral anticoagulant dabigatran does not require therapeutic drug monitoring, however emergency measurements are gaining importance. Current assays feature good performance at intermediate and high dabigatran concentrations but show limited accuracy at low concentrations. This area requires more attention as ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章

    doi：10.1007/s11239-019-01981-z

    authors： Härtig F,Poli S,Ebner M,Birschmann I,Kuhn J,Ziemann U,Häring HU,Lehmann R,Peter A,Hörber S

    更新日期：2020-04-01 00:00:00

  • Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry.

    abstract：:The optimal antithrombotic therapy for patients undergoing TAVI with concomitant indication for oral anticoagulation remains unclear. In this high-risk population group, there is a paucity of data with regards to the use of DOACs. In the present study we compared long-term clinical outcomes of TAVI patients requiring ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-019-01968-w

    authors： Kalogeras K,Jabbour RJ,Ruparelia N,Watson S,Kabir T,Naganuma T,Vavuranakis M,Nakamura S,Malik IS,Mikhail G,Dalby M,Panoulas V

    更新日期：2020-07-01 00:00:00

  • Impact of primary PCI volume on hospital mortality in STEMI patients: does time-to-presentation matter?

    abstract：:The exact relationship between primary percutaneous coronary intervention (PCI) volume and mortality remains unclear. No data are available on how this relationship could be affected by time-to-presentation. The primary aim of this study was to evaluate the impact of hospital primary PCI volume on in-hospital mortalit...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1007/s11239-011-0598-1

    authors： Navarese EP,De Servi S,Politi A,Martinoni A,Musumeci G,Boschetti E,Belli G,D'Urbano M,Piccaluga E,Lettieri C,Klugmann S

    更新日期：2011-08-01 00:00:00

  • Using big data to retrospectively validate the COMPASS-CAT risk assessment model: considerations on methodology.

    abstract：:External validation is a prerequisite in order for a prediction model to be introduced into clinical practice. Nonetheless, methodologically intact external validation studies are a scarce finding. Utilization of big datasets can help overcome several causes of methodological failure. However, transparent reporting is...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02191-8

    authors： Nikolakopoulos I,Nourabadi S,Eldredge JB,Anand L,Zhang M,Qiu M,Rosenberg D,Spyropoulos AC

    更新日期：2021-01-01 00:00:00

  • Persisting autoimmune heparin-induced thrombocytopenia after elective abdominal aortic aneurysm repair: a case report.

    abstract：:Persisting heparin-induced thrombocytopenia (HIT) is characterized by ongoing thrombocytopenia more than 7 days after stopping heparin. It is part of cases referred to as autoimmune HIT (aHIT). In contrast to typical HIT cases, aHIT involves heparin-independent platelet activation mechanism highlighted by a strongly p...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-020-02062-2

    authors： Roberge G,Tritschler T,MacGillivray C,Dufresne L,Nagpal SK,Scarvelis D

    更新日期：2020-10-01 00:00:00

  • A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocard

    abstract：:Thrombolytic therapy has become a standard treatment for selected patients with acute myocardial infarction (MI). Various thrombolytic agents have been shown to decrease mortality. However, current thrombolytic agents still suffer significant shortcomings, such as a low optimal reperfusion rate delayed reperfusion. an...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1023/a:1008872031770

    authors： Serebruany VL,Jang IK,Giugliano RP,Massey TJ,Schwarz Jr RP

    更新日期：1998-01-01 00:00:00

  • Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study.

    abstract：OBJECTIVE:We aimed to determine the relative level of platelet inhibition achieved with low-dose aspirin (81 mg daily) compared with a very low-dose (100 mg every other day). BACKGROUND:The Womens Health Study (WHS) found that a dose of 100 mg every other day of aspirin provided protection against stroke as primary pr...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 临床试验,杂志文章

    doi：10.1007/s11239-008-0262-6

    authors： Swaim L,Hillman RS

    更新日期：2009-07-01 00:00:00

  • Thrombolysis in Acute Myocardial Infarction Complicated by Cardiogenic Shock.

    abstract：:The adverse impact of the development of cardiogenic shock in the setting of acute myocardial infarction was first described by Killip and Kimball in 1967. While the in-hospital mortality rate in patients with myocardial infarction and no evidence of heart failure was only 6%, the mortality rate in those patients who ...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/BF01063156

    authors： Levine GN,Hochman JS

    更新日期：1995-01-01 00:00:00

  • Survey of confidence in use of stroke and bleeding risk calculators, knowledge of anticoagulants, and comfort with prescription of anticoagulation in challenging scenarios: SUPPORT-AF II study.

    abstract：:Half of patients with atrial fibrillation (AF) and elevated stroke risk do not receive anticoagulation (AC). Explanations for undertreatment may relate to provider lack of confidence with or knowledge of the CHA2DS2-VASc stroke calculator, unfamiliarity with direct oral anticoagulants (DOACs), or uncertainty about use...

    journal_title：Journal of thrombosis and thrombolysis

    pub_type： 杂志文章

    doi：10.1007/s11239-019-01950-6

    authors： Amroze A,Mazor K,Crawford S,O'Day K,McManus DD,Kapoor A

    更新日期：2019-11-01 00:00:00